Sacituzumab Govitecan-hziy in Refractory Metastatic Triple-Negative Breast Cancer
The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Standard chemotherapy is associated with low response rates and short progression-free survival among patients with pretreated metastatic triple-negative breast cancer. Sacituzumab govitecan-hziy is an antibody-drug conjugate that combines a humanized monoclonal antibody, which targets the human trophoblast cell-surface antigen 2 (Trop-2), with SN-38, which is conjugated to the antibody by a cleavable linker. Sacituzumab govitecan-hziy enables delivery of high concentrations of SN-38 to tumors. METHODS: We conducted a phase 1/2 single-group, multicenter trial involving patients with advanced epithelial cancers who received sacituzumab govitecan-hziy intravenously on days 1 and 8 of each 21-day cycle until disease progression or unacceptable toxic effects. A total of 108 patients received sacituzumab govitecan-hziy at a dose of 10 mg per kilogram of body weight after receiving at least two previous anticancer therapies for metastatic triple-negative breast cancer. The end points included safety; the objective response rate (according to Response Evaluation Criteria in Solid Tumors, version 1.1), which was assessed locally; the duration of response; the clinical benefit rate (defined as a complete or partial response or stable disease for at least 6 months); progression-free survival; and overall survival. Post hoc analyses determined the response rate and duration, which were assessed by blinded independent central review. RESULTS: The 108 patients with triple-negative breast cancer had received a median of 3 previous therapies (range, 2 to 10). Four deaths occurred during treatment; 3 patients (2.8%) discontinued treatment because of adverse events. Grade 3 or 4 adverse events (in ≥10% of the patients) included anemia and neutropenia; 10 patients (9.3%) had febrile neutropenia. The response rate (3 complete and 33 partial responses) was 33.3% (95% confidence interval [CI], 24.6 to 43.1), and the median duration of response was 7.7 months (95% CI, 4.9 to 10.8); as assessed by independent central review, these values were 34.3% and 9.1 months, respectively. The clinical benefit rate was 45.4%. Median progression-free survival was 5.5 months (95% CI, 4.1 to 6.3), and overall survival was 13.0 months (95% CI, 11.2 to 13.7). CONCLUSIONS: Sacituzumab govitecan-hziy was associated with durable objective responses in patients with heavily pretreated metastatic triple-negative breast cancer. Myelotoxic effects were the main adverse reactions. (Funded by Immunomedics; IMMU-132-01 ClinicalTrials.gov number, NCT01631552.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The overall response rate was 33.3% (95% CI 24.6-43.1), with a median duration of response of 7.7 months (95% CI 4.9-10.8).”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [72]
In the citing paper
“Of the patients with a response to sacituzumab govitecan-hziy, 55.6% maintained their response for ≥6 months and 16.7% maintained their response for ≥12 months.”
From 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5) (2020) · cites this paper as [72]
Citations
Cites
Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer
Schmid, P., Adams, S., Rugo, H. S., Schneeweiss, A., Barrios, C. H., Iwata, H., Diéras, V., Hegg, R., Im, S.-A., Shaw Wright, G., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809615 · Cited by 4,350
Self-citationTrastuzumab emtansine for HER2-positive advanced breast cancer
Verma, S., Miles, D., Gianni, L., Krop, I. E., Welslau, M., Baselga, J., Pegram, M., Oh, D.-Y., Diéras, V., Guardino, E., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1209124 · Cited by 3,834
Palbociclib and letrozole in advanced breast cancer
Finn, R. S., Martin, M., Rugo, H. S., Jones, S., Im, S.-A., Gelmon, K., Harbeck, N., Lipatov, O. N., Walshe, J. M., Moulder, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607303 · Cited by 3,007
Self-citationCombined BRAF and MEK inhibition in melanoma with BRAF V600 mutations
Flaherty, K. T., Infante, J. R., Daud, A., Gonzalez, R., Kefford, R. F., Sosman, J., Hamid, O., Schuchter, L., Cebon, J., Ibrahim, N., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1210093 · Cited by 2,810
Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer
Shaw, A. T., Ou, S.-H. I., Bang, Y.-J., Camidge, D. R., Solomon, B. J., Salgia, R., Riely, G. J., Varella-Garcia, M., Shapiro, G. I., Costa, D. B., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406766 · Cited by 1,964
Breast cancer statistics, 2015: Convergence of incidence rates between black and white women
DeSantis, C. E., Fedewa, S. A., Goding Sauer, A., Kramer, J. L., Smith, R. A., & Jemal, A. (2016) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21320 · Cited by 1,252
Cortes, J., O'Shaughnessy, J., Loesch, D., Blum, J. L., Vahdat, L. T., Petrakova, K., Chollet, P., Manikas, A., Diéras, V., Delozier, T., et al. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60070-6 · Cited by 1,094
Self-citationKohler, B. A., Sherman, R. L., Howlader, N., Jemal, A., Ryerson, A. B., Henry, K. A., Boscoe, F. P., Cronin, K. A., Lake, A., Noone, A.-M., et al. (2015) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djv048 · Cited by 915
Kawato, Y., Aonuma, M., Hirota, Y., Kuga, H., & Sato, K. (1991) · PubMed · Cited by 865
Goldenberg, D. M., Cardillo, T. M., Govindan, S. V., Rossi, E. A., & Sharkey, R. M. (2015) · Oncotarget · doi:10.18632/oncotarget.4318 · Cited by 495
Self-citation
Research works printed but not linked: 1
- 10.1002/(SICI)1097-0215(19980529)76:5<671::AID-IJC10>3.0.CO;2-7 · DOI · Paper page
Cited by
Items 101–200 of 874
DeLucia, D. C., Cardillo, T. M., Ang, L. S., Labrecque, M. P., Zhang, A., Hopkins, J. E., Sarkar, N. D., Coleman, I. M., da Costa, R. M. G., Corey, E., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-3396 · Cited by 92
Decary, S., Berne, P., Nicolazzi, C., Lefebvre, A., Dabdoubi, T., Cameron, B., Rival, P., Devaud, C., Prades, C., Bouchard, H., et al. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-4051 · Cited by 92
Emens, L. A., Adams, S., Cimino‐Mathews, A., Disis, M. L., Gatti-Mays, M. E., Ho, A. Y., Kalinsky, K. M., McArthur, H. L., Mittendorf, E. A., Nanda, R., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-002597 · Cited by 91
Self-citationRibeiro, R., Carvalho, M. J., Gonçalves, J., & Moreira, J. N. (2022) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2022.903065 · Cited by 89
“(Bardia et al., 2019), in April 2020, FDA granted accelerated approval to sacituzumab govitecan for patients with metastatic TNBC who received at least two prior treatments for the”
BackgroundYuan, Y., Lee, J. S., Yost, S. E., Frankel, P. H., Ruel, C., Egelston, C. A., Guo, W., Gillece, J. D., Folkerts, M., Reining, L., et al. (2020) · The Oncologist · doi:10.1002/onco.13583 · Cited by 91
“These include PARP inhibitors for BRCA mutated tumors [11, 12], immune checkpoint inhibitors for programmed death ligand-1 (PDL1)–positive TNBC [13], and antibody drug conjugate targeting Trop-2 receptor [14].”
BackgroundAntibody-Drug Conjugates in Breast Cancer: a Comprehensive Review
Ponde, N. F., Aftimos, P. G., & Piccart, M. J. (2019) · Current Treatment Options in Oncology · doi:10.1007/s11864-019-0633-6 · Cited by 86
The emerging roles of NGS in clinical oncology and personalized medicine
Hussen, B. M., Abdullah, S. T., Salihi, A. B., Sabir, D. K., Sidiq, K. R., Rasul, M. F., Hidayat, H. J., Ghafouri‐Fard, S., Taheri, M. N., & Jamali, E. (2022) · Pathology - Research and Practice · doi:10.1016/j.prp.2022.153760 · Cited by 98
Yoder, R., Kimler, B. F., Staley, J. M., Schwensen, K., Wang, Y. Y., Finke, K., O’Dea, A. P., Nye, L. E., Elia, M., Crane, G. J., et al. (2022) · npj Breast Cancer · doi:10.1038/s41523-022-00448-4 · Cited by 88
Drug resistance in breast cancer: Mechanisms and strategies for management
Wu, G., Xiao, M., Hao, W.-C., Yang, Z., Liu, X., Xu, D., Peng, Z.-X., & Zhang, L. (2025) · Drug Resistance Updates · doi:10.1016/j.drup.2025.101288 · Cited by 90
Advances in Targeted Therapies for Triple-Negative Breast Cancer
McCann, K. E., Hurvitz, S. A., & McAndrew, N. P. (2019) · Drugs · doi:10.1007/s40265-019-01155-4 · Cited by 90
Actively Targeted Nanomedicines in Breast Cancer: From Pre-Clinal Investigation to Clinic
Fraguas‐Sánchez, A. I., Lozza, I., & Torres‐Suárez, A. I. (2022) · Cancers · doi:10.3390/cancers14051198 · Cited by 84
“5% of patients with advanced metastatic breast cancer, and a median overall survival rate of around 13 months [62] without producing severe adverse effects.”
BackgroundThe Evolving Role of Neoadjuvant Therapy for Operable Breast Cancer
Spring, L. M., Bar, Y., & Isakoff, S. J. (2022) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2022.7016 · Cited by 89
“4547 The TROP2-directed antibody–drug conjugate sacituzumab govitecan is FDAapproved for the treatment of metastatic TNBC.(48) Current ongoing trials are evaluating the role of sacituzumab govitecan in the neoadjuvant (NeoSTAR, NCT04230109)”
BackgroundInfluentialSelf-citationCaputo, R., Buono, G., Piezzo, M., Martinelli, C., Cianniello, D., Rizzo, A., Pantano, F., Staropoli, N., Cangiano, R., Turano, S., et al. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1362641 · Cited by 93
“…approval in April 2020, based on the results of the phase 1-2 trial IMMU-132-01, where the treatment with sacituzumab govitecan, in a cohort of 108 patients with mTNBC, was associated with an objective response rate (ORR) of 33%, a median PFS of 5.5 months and a median OS of 13.0 months (10).”
MethodInfluentialTrophoblast cell-surface antigen 2 (TROP2) expression in triple-negative breast cancer
Jeon, Y., Jo, U., Hong, J., Gong, G., & Lee, H. J. (2022) · BMC Cancer · doi:10.1186/s12885-022-10076-7 · Cited by 87
“3% of patients showed complete response or partial response [20].”
BackgroundKaras, S., & Innocenti, F. (2021) · JCO Oncology Practice · doi:10.1200/op.21.00624 · Cited by 80
“The reduced dose for sacituzumab govitecan-hziy is based on the trial protocol dose reduction.(72) Abbreviations: FDA, US Food and Drug Administration; FOLFIRI, fluorouracil, leucovorin, and irinotecan; FOLFIRINOX, fluorouracil, leucovorin, irinotecan, and oxaliplatin; FOLFOXIRI, fluorouracil, folinic acid, oxaliplati…”
Advances in delivery of Irinotecan (CPT-11) active metabolite 7-ethyl-10-hydroxycamptothecin
Si, J., Zhao, X., Gao, S., Huang, D., & Sui, M. (2019) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2019.118499 · Cited by 77
CAR-T cell therapy in triple-negative breast cancer: Hunting the invisible devil
Nasiri, F., Kazemi, M., Mirarefin, S. M. J., Kancha, M. M., Najafabadi, M. A., Salem, F., Shokoohi, S. D., Bakhshi, S. E., Kozani, P. S., & Kozani, P. S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.1018786 · Cited by 81
Nanobodies as efficient drug-carriers: Progress and trends in chemotherapy
Panikar, S. S., Banu, N., Haramati, J., del Toro‐Arreola, S., Leal, A. R., & Salas, P. (2021) · Journal of Controlled Release · doi:10.1016/j.jconrel.2021.05.004 · Cited by 81
Classifications of triple-negative breast cancer: insights and current therapeutic approaches
Chen, Z., Liu, Y., Lyu, M., Chan, C. H., Sun, M., Yang, X., Qiao, S., Chen, Z., Yu, S., Ren, M., et al. (2025) · Cell & Bioscience · doi:10.1186/s13578-025-01359-0 · Cited by 92
Topoisomerases and cancer chemotherapy: recent advances and unanswered questions
Bjornsti, M., & Kaufmann, S. H. (2019) · F1000Research · doi:10.12688/f1000research.20201.1 · Cited by 81
Targeting HER2 expression in cancer: New drugs and new indications
Vranić, S., Bešlija, S., & Gatalica, Z. (2021) · Biomolecules and Biomedicine · doi:10.17305/bjbms.2020.4908 · Cited by 91
“trial (IMMU-132-01 (NCT 01631552) clinical trial [53].”
U.S. FDA Drug Approvals for Breast Cancer: A Decade in Review
Arora, S., Narayan, P., Osgood, C. L., Wedam, S. B., Prowell, T. M., Gao, J. J., Shah, M., Krol, D., Wahby, S., Royce, M., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-21-2600 · Cited by 82
Santin, A. D., Corr, B. R., Spira, A. I., Willmott, L. J., Butrynski, J. E., Tse, K. Y., Patel, J., Mekan, S. F., Wu, T., Lin, K.-W., et al. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.23.02767 · Cited by 85
“15,17,18 In the ASCENT phase III trial, overall survival (OS) was signi fi cantly longer with SG (12.1 months) than with chemotherapy (6.7 months) in patients with metastatic triple-negative breast cancer (mTNBC).”
BackgroundInfluentialSelf-citationImmunotherapy in Triple-Negative Breast Cancer
Emens, L. A. (2021) · The Cancer Journal · doi:10.1097/ppo.0000000000000497 · Cited by 81
Yao, H.-P., Zhao, H., Hudson, R., Tong, X.-M., & Wang, M.-H. (2021) · Drug Discovery Today · doi:10.1016/j.drudis.2021.06.012 · Cited by 70
A literature review of the promising future of TROP2: a potential drug therapy target
Wen, Y., Ouyang, D., Zou, Q., Chen, Q., Luo, N., He, H., Anwar, M., & Yi, W. (2022) · Annals of Translational Medicine · doi:10.21037/atm-22-5976 · Cited by 85
“The United States Food and Drug Administration (FDA) approved the application of sacituzumab on December 26, 2019, for triple-negative breast cancer (TNBC) patients who have received two or more prior therapies (NCT01631552) (4,62-64).”
BackgroundAntibody–Drug Conjugates for the Treatment of Breast Cancer
Corti, C., Giugliano, F., Nicolò, E., Ascione, L., & Curigliano, G. (2021) · Cancers · doi:10.3390/cancers13122898 · Cited by 79
“Sacituzumab govitecan (SG) is a newly approved ADC coupling an anti-TROP2 Ab with SN-38, the active metabolite of irinotecan [24].”
BackgroundChinese society of clinical oncology (CSCO) Breast Cancer Guidelines 2022
CSCO BC guideline working group, Jiang, Z., Song, E., Geng, C., Pan, Y., Wang, X., Wang, H., Wang, S., Wang, X., Wu, J., et al. (2022) · Translational Breast Cancer Research · doi:10.21037/tbcr-22-21 · Cited by 81
Zeybek, B., Manzano, A., Bianchi, A., Bonazzoli, E., Bellone, S., Buza, N., Hui, P., Lopez, S., Perrone, E., Manara, P., et al. (2020) · Scientific Reports · doi:10.1038/s41598-020-58009-3 · Cited by 68
Self-citationPerrone, E., Lopez, S., Zeybek, B., Bellone, S., Bonazzoli, E., Pelligra, S., Zammataro, L. A., Manzano, A., Manara, P., Bianchi, A., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00118 · Cited by 70
“SG was well tolerated with limited adverse treatment-related events (14, 15, 17, 31).”
BackgroundSelf-citationOncogene-mediated metabolic gene signature predicts breast cancer outcome
Aslan, M., Hsu, E., Garcia-Marques, F. J., Bermudez, A., Liu, S., Shen, M., West, M., Zhang, C. A., Rice, M. A., Brooks, J. D., et al. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00341-6 · Cited by 80
Anti-HER2 therapy in metastatic breast cancer: many choices and future directions
Wynn, C., & Tang, S. (2022) · Cancer and Metastasis Reviews · doi:10.1007/s10555-022-10021-x · Cited by 78
“Sacituzumab govitecan is an anti-Trop2SN-38 ADC that is approved for triple negative breast cancer [93] and has also shown promising results in HR + / HER2- MBC [94].”
BackgroundLeveraging TROP2 Antibody-Drug Conjugates in Solid Tumors
Nelson, B. E., & Meric‐Bernstam, F. (2023) · Annual Review of Medicine · doi:10.1146/annurev-med-071322-065903 · Cited by 78
Seligson, J. M., Patron, A. M., Berger, M. J., Harvey, R. D., & Seligson, N. D. (2020) · Annals of Pharmacotherapy · doi:10.1177/1060028020966548 · Cited by 70
Trop‐2 cleavage by ADAM10 is an activator switch for cancer growth and metastasis
Trerotola, M., Guerra, E., Ali, Z., Aloisi, A. L., Ceci, M., Simeone, P., Acciarito, A., Zanna, P. T., Vacca, G., D’Amore, A., et al. (2021) · Neoplasia · doi:10.1016/j.neo.2021.03.006 · Cited by 76
Current understandings and clinical translation of nanomedicines for breast cancer therapy
Jiang, Y., Jiang, Z., Wang, M., & Ma, L. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.114034 · Cited by 72
The Resurgence of Antibody Drug Conjugates in Cancer Therapeutics: Novel Targets and Payloads
Boni, V., Sharma, M. R., & Patnaik, A. (2020) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk_281107 · Cited by 64
Breast Cancer Therapeutics and Biomarkers: Past, Present, and Future Approaches
Schick, J., Ritchie, R. P., & Restini, C. B. A. (2021) · Breast Cancer Basic and Clinical Research · doi:10.1177/1178223421995854 · Cited by 74
You, K. S., Yi, Y. W., Cho, J., Park, J., & Seong, Y. (2021) · Pharmaceuticals · doi:10.3390/ph14060589 · Cited by 70
“Sacituzumab govitecan is an antibody drug conjugate (ADC) composed of a humanized monoclonal antibody for trophoblast cell surface antigen 2 (Trop-2) and topoisomerase inhibitor SN-38 [590].”
BackgroundBessede, A., Peyraud, F., Besse, B., Cousin, S., Cabart, M., Chomy, F., Rey, C., Lara, O., Odin, O., Nafia, I., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-23-2566 · Cited by 74
“In 2020, sacituzumab govitecan, an ADC targeting TROP2, became the fi rst FDA-approved anti-TROP2 agent for the treatment of unresectable locally advanced or metastatic triple-negative breast cancer in patients refractory to previous systemic therapies (20).”
BackgroundManagement of infusion-related reactions in cancer therapy: strategies and challenges
Barroso, A., Estevinho, F., Hespanhol, V. P., Teixeira, E., Ramalho-Carvalho, J., & Araújo, A. (2024) · ESMO Open · doi:10.1016/j.esmoop.2024.102922 · Cited by 85
Šubjaková, V., Oravczová, V., & Hianik, T. (2021) · Polymers · doi:10.3390/polym13030341 · Cited by 67
“anti-Trop-2 (Sacituzumab) SN-38 triple-negative breast cancer/Trop-2 Hydrolysable link, with short polyethylene glycol moiety(CL2A) [188,189]”
BackgroundAdvanced drug delivery system with nanomaterials for personalised medicine to treat breast cancer
Han, H. J., Ekweremadu, C., & Patel, N. (2019) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2019.05.024 · Cited by 62
Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer
Weiss, J. A., Glode, A. E., Messersmith, W. A., & Diamond, J. R. (2019) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2019.1654378 · Cited by 62
“with metastatic TNBC was similar to patients with other tumor types [32,33].”
BackgroundMethodResultSelf-citationVahdat, L. T., Schmid, P., Forero, A., Blackwell, K., Telli, M. L., Melisko, M., Möbus, V. J., Cortés, J., Montero, A. J., Ma, C. X., et al. (2021) · npj Breast Cancer · doi:10.1038/s41523-021-00244-6 · Cited by 63
Self-citationCardillo, T. M., Rossi, D. L., Zalath, M. B., Liu, D., Arrojo, R., Sharkey, R. M., Chang, C., & Goldenberg, D. M. (2020) · Oncotarget · doi:10.18632/oncotarget.27766 · Cited by 62
“SG demonstrated significant clinical benefit across a range of solid tumors, including metastatic TNBC (mTNBC) [10], hormone-positive breast cancer [11], small-cell lung cancer (SCLC) [12], non-small-cell lung cancer (NSCLC) [13], and metastatic urothelial carcinomas (mUC) [14, 15].”
BackgroundSelf-citationChen, H., Wei, F., Yin, M., Zhao, Q., Liu, Z., Yu, B., & Huang, Z. (2021) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-020-02838-8 · Cited by 63
Immunotherapy in Breast Cancer: When, How, and What Challenges?
Henriques, B., Mendes, F., & Martins, D. F. (2021) · Biomedicines · doi:10.3390/biomedicines9111687 · Cited by 70
“Recently another ADC was approved for TNBC BC, namely Sacituzumab Govitecanhziy, due to IMMU-132-01 clinical trial results, as observed in Table 1 [55,70].”
BackgroundMethodInfluentialPhase I study of A166, an antibody‒drug conjugate in advanced HER2-expressing solid tumours
Zhang, J., Liu, R., Gao, S., Li, W., Chen, Y., Meng, Y., Liu, C., Jin, W., Wu, J., Wang, Y., et al. (2023) · npj Breast Cancer · doi:10.1038/s41523-023-00522-5 · Cited by 59
“…AEs often associated with chemotherapy drugs, such as gastrointestinal, haematological and pulmonary toxicities (Supplementary Table 3) 18 – 20 , were observed in this study for A166 compared to other approved ADCs for breast cancer, further indicating that A166 may provide an opportunity…”
Research Progress of SN38 Drug Delivery System in Cancer Treatment
Qi, Q.-R., Tian, H., Yue, B., Zhai, B., & Zhao, F. H. (2024) · International Journal of Nanomedicine · doi:10.2147/ijn.s435407 · Cited by 63
Antibody-Drug Conjugates: A promising breakthrough in cancer therapy
Parit, S., Manchare, A., Gholap, A. D., Mundhe, P., Hatvate, N. T., Rojekar, S. V., & Patravale, V. B. (2024) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2024.124211 · Cited by 59
Wang, J., Liu, Y., Zhang, Q., Li, W., Feng, J., Wang, X., Fang, J., Han, Y., & Xu, B. (2024) · 癌症:英文版 · doi:10.1002/cac2.12577 · Cited by 68
“After the failure of second-line chemotherapy, there is no standard treatment available, and sacituzumab govitecan (SG) can be used for patients with triple-negative breast cancer but not for Hormone receptor (HR) + /HER2-ABC in China [9, 10].”
BackgroundLi, W., Guo, H., Li, L., Zhang, Y., & Cui, J. (2021) · Cancer Medicine · doi:10.1002/cam4.4052 · Cited by 62
Trophoblast Cell Surface Antigen 2 gene (TACSTD2) expression in primary breast cancer
Vidula, N., Yau, C. S. F., & Rugo, H. S. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06660-x · Cited by 59
Self-citationGatti-Mays, M. E., Karzai, F. H., Soltani, S. N., Zimmer, A. S., Green, J. E., Lee, M.-J., Trepel, J. B., Yuno, A., Lipkowitz, S., Nair, J. R., et al. (2020) · The Oncologist · doi:10.1634/theoncologist.2020-0491 · Cited by 64
Recent advances in trophoblast cell‐surface antigen 2 targeted therapy for solid tumors
Liao, S., Wang, B., Zeng, R., Bao, H., Chen, X., Dixit, R., & Xing, X. (2021) · Drug Development Research · doi:10.1002/ddr.21870 · Cited by 60
“…region for protein–protein interactions, as well as contains a protein kinase C (PKC) phosphorylation site and a phosphatidyl-inositol 4,5-bisphosphate (PIP2) binding sequence, supporting the role of Trop 2 in calcium signaling (Basu et al., 1995; Ciccarelli et al., 2000; El Sewedy et al., 1998).”
BackgroundBardia, A., Sun, S., Thimmiah, N., Coates, J. T. T., Wu, B., Abelman, R. O., Spring, L. M., Moy, B., Ryan, P. K., Melkonyan, M. N., et al. (2024) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-24-0428 · Cited by 60
Self-citationFenn, K. M., & Kalinsky, K. M. (2019) · Drugs of today · doi:10.1358/dot.2019.55.9.3039669 · Cited by 62
Self-citationSaini, K. S., Punie, K., Twelves, C. J., Bortini, S., de Azambuja, E., Anderson, S., Criscitiello, C., Awada, A. H., & Loi, S. (2021) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1936494 · Cited by 62
Targeting triple-negative breast cancer: A clinical perspective
POPOVIC, L. S., Matovina-Brko, G., Popovic, M., Punie, K., Cvetanović, A., & Lambertini, M. (2023) · Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics · doi:10.32604/or.2023.028525 · Cited by 66
Challenges and Opportunities in Developing Targeted Therapies for Triple Negative Breast Cancer
Chapdelaine, A. G., & Sun, G. (2023) · Biomolecules · doi:10.3390/biom13081207 · Cited by 63
Trop2 is upregulated in the transition to dysplasia in the metaplastic gastric mucosa
Riera, K. M., Jang, B. G., Min, J., Roland, J. T., Yang, Q., Fesmire, W. T., Camilleri‐Broët, S., Ferri, L. E., Kim, W. H., Choi, E.-Y. K., et al. (2020) · The Journal of Pathology · doi:10.1002/path.5469 · Cited by 61
“Treatment with sacituzumab govitecan (IMMU-132), an antibody drug conjugate of SN-38 (a topoisomerase I inhibitor) that is coupled to an anti-Trop2 monoclonal antibody, had promising results for patients with refractory metastatic triplenegative breast cancer [35].”
BackgroundAssidicky, R., Tokat, Ü. M., Tarman, I. O., Saatci, Ö., Ersan, P. G., Raza, U., Oğul, H., Riazalhosseini, Y., Can, T., & Şahin, Ö. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06569-5 · Cited by 58
“, atezolizumab [10], and the antibody–drug conjugate, Sacituzumab govitecan-hziy [12] in refractory, metastatic TNBCs, the improvement in progression-free survival is limited, which necessitates the identification of novel therapy options that can improve survival rates in TNBCs.”
BackgroundExpression and Therapeutic Targeting of TROP-2 in Treatment-Resistant Prostate Cancer
Sperger, J. M., Helzer, K. T., Stahlfeld, C. N., Jiang, D., Singh, A., Kaufmann, K. R., Niles, D. J., Héninger, E., Rydzewski, N. R., Wang, L., et al. (2023) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-22-1305 · Cited by 58
“TROP-2 has emerged as a promising target outside the AR signaling axis and has been successfully used as a drug target in other malignancies (10, 16, 17, 44 – 46).”
Adams, E., Wildiers, H. P. M. W., Neven, P., & Punie, K. (2021) · ESMO Open · doi:10.1016/j.esmoop.2021.100204 · Cited by 58
“The ADC has a high drug-to-antibody ratio of 7.6 SN-38 molecules per antibody.20 In April 2020, SG received accelerated FDA approval for mTNBC in patients who received two prior regimens for metastatic disease based on efficacy and safety data from a phase I/II basket study, IMMU-13201.”
BackgroundMethodInfluentialA role of FDG-PET/CT for response evaluation in metastatic breast cancer?
Hildebrandt, M. G., Naghavi‐Behzad, M., & Vogsen, M. (2022) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2022.03.004 · Cited by 59
Maiti, R., Patel, B., Patel, N., Patel, M. M., Patel, A., & Dhanesha, N. (2023) · Archives of Pharmacal Research · doi:10.1007/s12272-023-01447-0 · Cited by 58
Clinical Development of New Antibody–Drug Conjugates in Breast Cancer: To Infinity and Beyond
Barroso‐Sousa, R., & Tolaney, S. M. (2021) · BioDrugs · doi:10.1007/s40259-021-00472-z · Cited by 57
Self-citationRosenbaum, D., & Säftig, P. (2023) · FEBS Journal · doi:10.1111/febs.16870 · Cited by 60
“) that is successfully being used in patients with metastatic triple-negative breast cancer (TNBC) is of clinical interest [48].”
BackgroundZhang, X., Ou, C., Liu, H., Prabhu, S. K., Li, C., Yang, Q., & Wang, L. (2021) · ACS Chemical Biology · doi:10.1021/acschembio.1c00597 · Cited by 54
Assessment of PD-L1, TROP2, and nectin-4 expression in penile squamous cell carcinoma
Tekin, B., Cheville, J. C., Hernandez, L. H., Negron, V. C., Smith, C. Y., Jenkins, S. M., Dasari, S., Enninga, E. A. L., Norgan, A. P., Menon, S. G., et al. (2023) · Human Pathology · doi:10.1016/j.humpath.2023.10.003 · Cited by 52
McGuinness, J. E., & Kalinsky, K. M. (2020) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2021.1840547 · Cited by 56
Self-citationSkinner, K. E., Haiderali, A., Huang, M., & Schwartzberg, L. S. (2020) · Future Oncology · doi:10.2217/fon-2020-1021 · Cited by 54
Torres, E. T. R., & Emens, L. A. (2021) · Breast Cancer Research and Treatment · doi:10.1007/s10549-021-06423-0 · Cited by 55
Preclinical activity of sacituzumab govitecan (IMMU-132) in uterine and ovarian carcinosarcomas
Lopez, S., Perrone, E., Bellone, S., Bonazzoli, E., Zeybek, B., Han, C., Tymon‐Rosario, J., Altwerger, G. H., Menderes, G., Bianchi, A., et al. (2020) · Oncotarget · doi:10.18632/oncotarget.27342 · Cited by 51
“Myelotoxic effects were the main adverse reactions [28].”
BackgroundResultSelf-citationTriple-Negative Breast Cancer: A Review of Current Curative Intent Therapies
MacDonald, I., Nixon, N. A., & Khan, O. F. (2022) · Current Oncology · doi:10.3390/curroncol29070378 · Cited by 55
“These include sacituzumab govitecan (an ADC consisting of an antibody targeting the human trophoblast cell-surface antigen 2 (Trop-2) linked to SN-38, a potent topoisomerase inhibitor) [25], as well as trastuzumab deruxtecan (an ADC consisting of an antibody targeting the HER-2 receptor linked to another topoisomerase…”
BackgroundBodyak, N. D., Mosher, R. E., Yurkovetskiy, A. V., Yin, M., Bu, C., Conlon, P. R., Demady, D. R., DeVit, M. J., Gumerov, D. R., Gurijala, V. R., et al. (2021) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0183 · Cited by 56
Glycans as Targets for Drug Delivery in Cancer
Diniz, F., Coelho, P., Duarte, H. O., Sarmento, B. F. C. C., Reis, C. A., & Gomes, J. (2022) · Cancers · doi:10.3390/cancers14040911 · Cited by 55
“deruxtecan [84] (approved for metastatic ErbB2-positive breast cancer) and sacituzumab govitecan [85] (indicated for triple-negative breast cancer).”
BackgroundImmunoPET of trophoblast cell-surface antigen 2 (Trop-2) expression in pancreatic cancer
Chen, W., Li, M., Younis, M. H., Barnhart, T. E., Jiang, D., Sun, T., Lang, J. M., Engle, J. W., Zhou, M., & Cai, W. (2021) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-021-05563-1 · Cited by 49
Recent Advances in Natural Product-Based Hybrids as Anti-Cancer Agents
Sflakidou, E., Leonidis, G., Foroglou, E., Siokatas, C., & Sarli, V. (2022) · Molecules · doi:10.3390/molecules27196632 · Cited by 52
Izci, H., Punie, K., Waumans, L., Laenen, A., Wildiers, H. P. M. W., Verdoodt, F., Desmedt, C., Ardui, J., Smeets, A., Han, S., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-27093-y · Cited by 53
Zhou, K., Liu, X., & Zhu, H. (2025) · Journal of Hematology & Oncology · doi:10.1186/s13045-025-01752-9 · Cited by 63
Druggable Molecular Targets for the Treatment of Triple Negative Breast Cancer
Nakhjavani, M., Hardingham, J. E., Palethorpe, H. M., Price, T. J., & Townsend, A. R. (2019) · Journal of Breast Cancer · doi:10.4048/jbc.2019.22.e39 · Cited by 55
“The main adverse reactions were myelotoxic effects [75].”
BackgroundPerrone, E., Manara, P., Lopez, S., Bellone, S., Bonazzoli, E., Manzano, A., Zammataro, L. A., Bianchi, A., Zeybek, B., Buza, N., et al. (2019) · Molecular Oncology · doi:10.1002/1878-0261.12627 · Cited by 49
“Consistent with our preclinical in vitro and in vivo results in biologically aggressive endometrial cancer, results from a phase I/II clinical study reported acceptable toxicity and encouraging therapeutic activity of SG against multiple recurrent human epithelial cancers including urothelial cancers and lung cancers…”
BackgroundResultSelf-citationPIK3Cδ expression by fibroblasts promotes triple-negative breast cancer progression
Gagliano, T., Shah, K., Gargani, S., Lao, L., Alsaleem, M. A., Chen, J., Ntafis, V., Huang, P., Ditsiou, A., Vella, V., et al. (2020) · Journal of Clinical Investigation · doi:10.1172/jci128313 · Cited by 50
Ünal, T., Hamurcu, Z., Delibaşı, N., Çınar, V., Güler, A., Gökçe, S., Nurdinov, N. S., & Ozpolat, B. (2020) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520620666200807221047 · Cited by 49
Klec, C., Knutsen, E., Schwarzenbacher, D., Jonas, K., Pasculli, B., Heitzer, E., Rinner, B., Krajina, K., Prinz, F., Gottschalk, B., et al. (2022) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-022-04402-2 · Cited by 51
Extracellular ATP promotes breast cancer chemoresistance via HIF-1α signaling
Yang, H., Geng, Y., Wang, P., Zhang, H., Fang, W., & Tian, X. (2022) · Cell Death and Disease · doi:10.1038/s41419-022-04647-6 · Cited by 57
Chen, Z., Liu, M., Wang, N., Xiao, W., & Shi, J. (2024) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c02115 · Cited by 55
Balinda, H. U., Kelly, W., Kaklamani, V., Lathrop, K. I., Canola, M. M., Ghamasaee, P., Sareddy, G. R., Michalek, J. E., Gilbert, A., Surapaneni, P., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-50558-9 · Cited by 60
“Among heavily pretreated metastatic TNBC (mTNBC), an overall response rate (ORR) of 33.3% and promising survival signals were observed and this lead to conditional FDA approval 20,21 .”
InfluentialO’Shaughnessy, J., Brufsky, A., Rugo, H. S., Tolaney, S. M., Punie, K., Sardesai, S. D., Hamilton, E. P., Loirat, D., Traina, T. A., Leon-Ferre, R. A., et al. (2022) · Breast Cancer Research and Treatment · doi:10.1007/s10549-022-06602-7 · Cited by 49
“0 months, and a manageable safety profile [24].”
BackgroundSelf-citationAnderson, M. G., Falls, H. D., Mitten, M. J., Oleksijew, A., Vaidya, K. S., Boghaert, E. R., Gao, W., Palma, J. P., Cao, D., Chia, P.-L., et al. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0149 · Cited by 49
Sachdev, J. C., Münster, P. N., Northfelt, D., Han, H. S., Ma, C. X., Maxwell, F., Wang, T. L., Belanger, B., Zhang, B., Moore, Y., et al. (2020) · Breast Cancer Research and Treatment · doi:10.1007/s10549-020-05995-7 · Cited by 48
CATCH: A Prospective Precision Oncology Trial in Metastatic Breast Cancer
Hlevnjak, M., Schulze, M., Elgaafary, S., Fremd, C., Michel, L. L., Beck, K., Pfütze, K., Richter, D., Wolf, S., Horak, P., et al. (2021) · JCO Precision Oncology · doi:10.1200/po.20.00248 · Cited by 53
Bai, X., Ni, J., Beretov, J., Graham, P., & Li, Y. (2021) · Journal of the National Cancer Center · doi:10.1016/j.jncc.2021.06.001 · Cited by 60
“For example, antibody-drug conjugate sacituzumab govitecan documented a ben-efit rate of 45.4% in refractory metastatic TNBC and is approved by the FDA in 2019 77 .”
BackgroundInfluentialXing, Z., Wang, R., Wang, X., Liu, J., Zhang, M., Feng, K., & Wang, X. (2021) · Cell Death Discovery · doi:10.1038/s41420-021-00604-y · Cited by 47
“Although great efforts have been made in etiological tracing research, limited progress has been achieved due to imprecise targeted treatments [4, 5].”
BackgroundImmunotherapy in triple-negative breast cancer: A literature review and new advances
Valencia, G., Rioja, P., Morante, Z., Ruiz, R., Fuentes, H. A., Castañeda, C. A., Vidaurre, T., Neciosup, S. P., & Gómez, H. (2022) · World Journal of Clinical Oncology · doi:10.5306/wjco.v13.i3.219 · Cited by 50
Emerging Therapeutics for Patients with Triple-Negative Breast Cancer
Agostinetto, E., Eiger, D., Punie, K., & de Azambuja, E. (2021) · Current Oncology Reports · doi:10.1007/s11912-021-01038-6 · Cited by 48
Trop-2 induces ADAM10-mediated cleavage of E-cadherin and drives EMT-less metastasis in colon cancer
Guerra, E., Trerotola, M., Relli, V., Lattanzio, R., Tripaldi, R., Vacca, G., Ceci, M., Boujnah, K., Garbo, V., Moschella, A., et al. (2021) · Neoplasia · doi:10.1016/j.neo.2021.07.002 · Cited by 55
“Sacituzumab govitecan-hziy is an anti-Trop-2 antibody-SN-38 drug conjugate, which was shown to be effective in metastatic breast cancer [14-17] and was granted accelerated FDA approval as Trodelvy, for use in the clinics.”
Bispecific antibody targeting TROP2xCD3 suppresses tumor growth of triple negative breast cancer
Liu, H., Bai, L., Huang, L., Ning, N., Li, L., Li, Y., Dong, X., Du, Q., Xia, M., Chen, Y., et al. (2021) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2021-003468 · Cited by 48
Metadata
- Authors
- Bardia, A., Mayer, I. A., Vahdat, L. T., Tolaney, S. M., Isakoff, S. J., Diamond, J. R., O’Shaughnessy, J., Moroose, R. L., Santin, A. D., Abramson, V. G., Shah, N. C., Rugo, H. S., Goldenberg, D. M., Sweidan, A. M., Iannone, R., Washkowitz, S., Sharkey, R. M., Wegener, W. A., & Kalinsky, K.
- Affiliations
- Harvard University (US)
- Vanderbilt University (US)
- Cornell University (US)
- Orlando Health (US)
- University of California, San Francisco (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-02-21
- Volume
- 380
- Issue
- 8
- Pages
- 741-751
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2917403028
- Cited by
- 874
- References
- 37
- Citations by year
- 2026: 76 · 2025: 103 · 2024: 111 · 2023: 125 · 2022: 167 · 2021: 167 · 2020: 91 · 2019: 32
- FWCI
- 36.24
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Immunomedics Inc
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Health Sciences › Medicine › Oncology › Advanced Breast Cancer Therapies
- Health Sciences › Medicine › Oncology › Cancer Treatment and Pharmacology
- Keywords
- sacituzumab govitecan, antibody-drug conjugates, metastatic triple-negative breast cancer, TROP2, SN-38, refractory disease, objective response rate, duration of response, progression-free survival, overall survival, safety, febrile neutropenia, anemia, neutropenia
- MeSH terms
- Irinotecan, Progression-Free Survival, Adult, Aged, Aged, 80 and over, Anemia, Antigens, Neoplasm, Antineoplastic Agents, Camptothecin, Diarrhea, Dose-Response Relationship, Drug, Female, Humans, Infusions, Intravenous, Male, Middle Aged, Neutropenia, Cell Adhesion Molecules, Survival Rate, Immunoconjugates, Antibodies, Monoclonal, Humanized, Triple Negative Breast Neoplasms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.